ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2268

Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity

Xihua Cao1, Jeffrey N. Miner2, Robert Terkeltaub3,4 and Ru Liu-Bryan1,4, 1VA Medical Center, San Diego, CA, 2Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, 3Rheumatology, VA Medical Center, San Diego, CA, 4Medicine-Rheumatology, University of California, San Diego, La Jolla, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: gout, hyperuricemia, inflammation and metabolism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Innate Immunity and Rheumatic Disease - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and developing gout. Fructose is well recognized to elevate serum uric acid via increased hepatic uric acid production through ATP consumption needed to metabolize fructose. Specifically, fructose metabolism in multiple cell types can lead to ATP depletion, and generation of AMP, and also of uric acid through xanthine oxidase (XO). The objective of this study was to test the hypothesis that fructose is pro-inflammatory in vitro in human monocyte-macrophage lineage cells, which play a major role in initiating and regulating the gout inflammation cascade. In doing so, we examined the roles of fructose stimulated uric acid generation. Soluble uric acid decreases hepatocyte activity of AMP-activated protein kinase (AMPK), a constitutive master inhibitor of inflammatory responses to urate crystals. AMPK tissue activity is decreased in obesity and diabetes.

Methods: Human monocytic THP-1 cells were cultured in RPMI media (1% FCS) containing 5 mM glucose for 24 hours. Fructose (5 or 15 mM) was then added to the media, and cells were cultured for additional 48 hours. For controls, glucose (2, 5 or 15 mM) was used instead of fructose. In some cases, febuxostat (xanthine oxidease inhibitor, 1 µM)) was added 30 min before addition of fructose. To determine the effect on fructose on inflammatory potential of THP-1 cells, twenty-four hours after addition of fructose, the cells were treated with LPS (1µg/ml) for another 24 hours. Expression of total AMPKα, Thr172 phosphorylated AMPKα indicative of AMPK activation, andexpression of AMP deaminase 1 (AMPD1) were examined by Western blot analysis. Inflammatory cytokine and chemokine IL-1β and CXCL8, respectively, were measured by ELISA.

Results: Decreased phosphorylation of AMPKα, correlated with increased expression of AMPD1, were observed in THP-1 cells in response to fructose, but not glucose, at 5 and 15 mM concentrations. In addition, these effects were inhibited by febuxostat, suggesting dependence of endogenous uric acid generation. In comparison, fructose at 2 mM concentration had no effect on phosphorylation of AMPKa and expression of AMPD1. Moreover, inflammatory potential of THP-1 cells was enhanced by fructose, evidenced by significantly increased LPS-induced expression of IL-1β and CXCL8 (by ~30% and 20%, respectively).

Conclusion: Excessive dietary fructose can increase peripheral monocyte inflammatory potential by reducing AMPK activity, in association with endogenously cell-generated uric acid. These observations may contribute to the marked increase in risk of developing gouty arthritis in those with high dietary fructose.


Disclosure: X. Cao, None; J. N. Miner, Ardea Biosciences, Inc., a member of the AstraZeneca Group, 3; R. Terkeltaub, Aequus BioPharma, 5,Ardea/Astra-Zeneca, 5,Revive, 5,SOBI, 5,Selecta, 5,Relburn, 5,ProThera, 5,Horizon, 5; R. Liu-Bryan, AstraZeneca, 2.

To cite this abstract in AMA style:

Cao X, Miner JN, Terkeltaub R, Liu-Bryan R. Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/fructose-amplifies-inflammatory-potential-in-human-monocytic-cells-via-reduction-of-amp-activated-protein-kinase-activity/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fructose-amplifies-inflammatory-potential-in-human-monocytic-cells-via-reduction-of-amp-activated-protein-kinase-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology